# Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis

> **NCT02907749** · PHASE4 · COMPLETED · sponsor: **Changqing Yang** · enrollment: 96 (actual)

## Conditions studied

- Cirrhosis
- Portal Hypertension

## Interventions

- **DRUG:** Spironolactone and carvedilol
- **DRUG:** Carvedilol

## Key facts

- **NCT ID:** NCT02907749
- **Lead sponsor:** Changqing Yang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-07-31
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02907749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02907749, "Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02907749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*